results of mino in MS

[Guest guest]

Norman posted this on cpnhelp, I thought it might be a pretty strong

result:

" Despite a moderately high pretreatment annualized relapse rate

(1.3/year pre-enrolment; 1.2/year during a three-month baseline

period) prior to treatment, no relapses occurred between months 6 and

24. Also, despite very active MRI activity pretreatment (19/40 scans

had gadolinium-enhancing activity during a three-month run-in), the

only patient with gadolinium-enhancing lesions on MRI at 12 and 24

months was on half-dose minocycline. "

I don't have the full text. Since the number of subjects is not given

in the abstract, it's hard to interpret the significance of the

numbers with certainty.

Mult Scler. 2007 May;13(4):517-26. Epub 2007 Feb 9.Click here to read

Links

The clinical response to minocycline in multiple sclerosis is

accompanied by beneficial immune changes: a pilot study.

Zabad RK, Metz LM, Todoruk TR, Zhang Y, JR, Yeung M,

Patry DG, Bell RB, Yong VW.

Department of Clinical Neurosciences, University of Calgary,

Calgary, Alberta, Canada.

Minocycline has immunomodulatory and neuroprotective activities in

vitro and in an animal model of multiple sclerosis (MS). We have

previously reported that minocycline decreased gadolinium-enhancing

activity over six months in a small trial of patients with active

relapsing-remitting MS (RRMS). Here we report the impact of oral

minocycline on clinical and magnetic resonance imaging (MRI) outcomes

and serum immune molecules in this cohort over 24 months of open-label

minocycline treatment. Despite a moderately high pretreatment

annualized relapse rate (1.3/year pre-enrolment; 1.2/year during a

three-month baseline period) prior to treatment, no relapses occurred

between months 6 and 24. Also, despite very active MRI activity

pretreatment (19/40 scans had gadolinium-enhancing activity during a

three-month run-in), the only patient with gadolinium-enhancing

lesions on MRI at 12 and 24 months was on half-dose minocycline.

Levels of the p40 subunit of interleukin (IL)-12, which at high levels

might antagonize the proinflammatory IL-12 receptor, were elevated

over 18 months of treatment, as were levels of soluble vascular cell

adhesion molecule-1. The activity of matrix metalloproteinase-9 was

decreased by treatment. Thus, clinical and MRI outcomes are supported

by systemic immunological changes and call for further investigation

of minocycline in MS. Multiple Sclerosis 2007; 13: 517-526.

http://msj.sagepub.com.

PMID: 17463074 [PubMed - in process]